Literature DB >> 1597451

Triplex formation prevents Sp1 binding to the dihydrofolate reductase promoter.

J E Gee1, S Blume, R C Snyder, R Ray, D M Miller.   

Abstract

The human dihydrofolate reductase (DHFR) promoter sequence contains two consensus binding sites for the Sp1 regulatory protein. We have determined the effect of intermolecular triplex DNA formation on Sp1 binding to the DHFR promoter. The DHFR Sp1 binding site I (-39 to -48 relative to the DHFR transcription start site) demonstrates concentration-dependent triplex formation with a 19-base pair G-rich oligonucleotide (GR19) which is complementary to the polypyrimidine strand. DNase I footprint analysis demonstrates that GR19 forms a DNA triplex structure with the DHFR promoter fragment in a sequence-specific manner. DNase I footprinting analysis also indicates that the orientation of binding of these G-rich oligonucleotides is antiparallel. CR19, a C-rich complementary oligonucleotide, on the other hand, does not form triplex. The DNase I protection pattern of DHFR promoter fragment incubated with both recombinant Sp1 and triplex-forming oligonucleotide suggests that triplex formation prevents Sp1 binding. This is confirmed by gel shift analysis which demonstrates that triplex formation by the Sp1 binding sequences of the DHFR promoter prevents recombinant Sp1 binding in a concentration-dependent manner. These results demonstrate that intermolecular triplex formation prevents regulatory protein binding in a sequence-specific manner.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1597451

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin.

Authors:  Vladimir Petrovic; Robert H Costa; Lester F Lau; Pradip Raychaudhuri; Angela L Tyner
Journal:  Cancer Biol Ther       Date:  2010-06-06       Impact factor: 4.742

2.  Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes.

Authors:  Kerstin-Maike Schmitz; Christine Mayer; Anna Postepska; Ingrid Grummt
Journal:  Genes Dev       Date:  2010-10-15       Impact factor: 11.361

Review 3.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

4.  Divalent transition metal cations counteract potassium-induced quadruplex assembly of oligo(dG) sequences.

Authors:  S W Blume; V Guarcello; W Zacharias; D M Miller
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

5.  Triplex targeting of human PDGF-B (c-sis, proto-oncogene) promoter specifically inhibits factors binding and PDGF-B transcription.

Authors:  J Liu; R Xu; Y Jin; D Wang
Journal:  Nucleic Acids Res       Date:  2001-02-01       Impact factor: 16.971

6.  Effect of competing self-structure on triplex formation with purine-rich oligodeoxynucleotides containing GA repeats.

Authors:  S B Noonberg; J C François; T Garestier; C Hélène
Journal:  Nucleic Acids Res       Date:  1995-06-11       Impact factor: 16.971

7.  Identification and characterization of a human herpesvirus 6 gene segment capable of transactivating the human immunodeficiency virus type 1 long terminal repeat in an Sp1 binding site-dependent manner.

Authors:  J Wang; C Jones; M Norcross; E Bohnlein; A Razzaque
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Effect of abasic linker substitution on triplex formation, Sp1 binding, and specificity in an oligonucleotide targeted to the human Ha-ras promoter.

Authors:  C Mayfield; D Miller
Journal:  Nucleic Acids Res       Date:  1994-05-25       Impact factor: 16.971

9.  Inhibition of transcription by platinated triplex-forming oligonucleotides.

Authors:  Mindy K Graham; Paul S Miller
Journal:  J Biol Inorg Chem       Date:  2012-09-11       Impact factor: 3.358

10.  Triplex-DNA stabilization by hydralazine and the presence of anti-(triplex DNA) antibodies in patients treated with hydralazine.

Authors:  T J Thomas; J R Seibold; L E Adams; E V Hess
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.